^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SENTI-301A

    i
    Other names: SENTI-301A, SENTI-301, SN301A
    Associations

    News

    Trials
    Company:
    Celest Therap, Senti Bio
    Drug class:
    GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    27d
    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    cyclophosphamide • fludarabine IV • SENTI-301A
    almost2years
    SENTI-301A, an off-the-shelf multi-armed preclinical CAR-NK cell therapy, for the treatment of GPC3 expressing tumors (AACR 2023)
    SENTI-301A is a novel off-the-shelf preclinical CAR-NK cell therapy candidate that targets GPC3-expressing tumors in an antigen-specific manner and exhibits increased persistence via crIL-15. We are exploring the potential synergy between SENTI-301A and CPIs to enhance the existing antitumor functions of SENTI-301A. SENTI-301A is planned for clinical development with an investigational new drug application (IND) expected in 2023.
    Preclinical
    |
    IFNG (Interferon, gamma) • GPC3 (Glypican 3) • GZMB (Granzyme B) • IL15 (Interleukin 15)
    |
    GPC3 expression
    |
    SENTI-301A